STRO-004 Clinical Learnings: How ADC Design Shapes Safety & Efficacy
4:45 pm - Wednesday 10th March 2027
- Tracing STRO-004’s development from antibody engineering and linker–payload design to its potential clinical differentiation among ADC therapies
- Presenting new Phase I safety and pharmacokinetic data for tissue factor–targeted STRO-004, including translation from cynomolgus monkey studies and implications for therapeutic index
- Examining the design rationale and development of dual-payload ADCs to address resistance to single-payload therapies.